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Abstract
NFκB is implicated in cancer and bone remodelling, and we have recently reported that the veriied NFκB inhibitor Parthe-
nolide (PTN) reduced osteolysis and skeletal tumour growth in models of metastatic breast cancer. Here, we took advantage 
of in vitro and ex vivo bone cell and organ cultures to study the efects of PTN on the ability of prostate cancer cells and 
their derived factors to regulate bone cell activity and osteolysis. PTN inhibited the in vitro growth of a panel of human, 
mouse and rat prostate cancer cells in a concentration-dependent manner with a varying degree of potency. In prostate can-
cer cell—osteoclast co-cultures, the rat Mat-Ly-Lu, but not human PC3 or mouse RM1-BT, enhanced RANKL stimulated 
osteoclast formation and PTN reduced these efects without afecting prostate cancer cell viability. In the absence of cancer 
cells, PTN reduced the support of Mat-Ly-Lu conditioned medium for the adhesion and spreading of osteoclast precursors, 
and survival of mature osteoclasts. Pre-exposure of osteoblasts to PTN prior to the addition of conditioned medium from 
Mat-Ly-Lu cells suppressed their ability to support the formation of osteoclasts by inhibition of RANKL/OPG ratio. PTN 
enhanced the ability of Mat-Ly-Lu derived factors to increase calvarial osteoblast diferentiation and growth. Ex vivo, PTN 
enhanced bone volume in calvaria organ—Mat-Ly-Lu cell co-culture, without afecting Mat-Ly-Lu viability or apoptosis. 
Mechanistic studies in osteoclasts and osteoblasts conirmed that PTN inhibit NFκB activation related to derived factors 
from Mat-Ly-Lu cells. Collectively, these indings suggest that pharmacological inhibition of the skeletal NFκB signalling 
pathway reduces prostate cancer related osteolysis, but further studies in the therapeutic implications of NFκB inhibition in 
cells of the osteoblastic lineage are needed.
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Abbreviations
PTN  Parthenolide
NFκ  Nuclear factor kappa-B
RANK  Receptor activator of NFκΒ
RANKL  RANK ligand
TNFα  Tumour necrosis factor alpha
IL1β  Interleukin 1 beta
CD40L  Cluster of diferentiation 40 ligand
TRAF  TNF receptor-associated factor
IKK  IκB kinase
TGFβ  Transforming growth factor beta
Runx2  Runt related transcription factor 2
M-CSF  Macrophage colony-stimulating factor
DMSO  Dimethyl sulfoxide
microCT  Micro–computed tomography
OPG  Osteoprotegerin
TRAcP  Tartrate-resistant acid phosphatase
Alk Phos  Alkaline phosphatase
ALZ  Alizarin red
BM  Bone marrow
ANOVA  Analysis of variance
SD  Standard deviation
Introduction
NFκB is implicated in cancer and bone remodelling 
[1–9]. Previous studies have shown that pharmacological 
and genetic inhibition of key components of the NFκB 
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signalling pathway reduce bone loss associated with vari-
ous bone disorders including bone metastasis, oestrogen 
deiciency, rheumatoid arthritis and Paget’s disease of 
bone [10–14]. The canonical NFκB signalling pathway 
consists of a family of transcription factors. Stimulation 
of receptors for various bone- and tumour-derived factors 
including receptor activator of NFκB ligand (RANKL), 
tumour necrosis factor alpha (TNFα), cluster of diferen-
tiation 40 ligand (CD40L) and interleukin-1 (IL-1) triggers 
a series of events that include the recruitment of adaptor 
proteins such as TRAF2 and 6 to the receptor, the assem-
bly of the inhibitor of IκB (IKK) complex and the phos-
phorylation and subsequent proteasomal degradation of 
IκB units leading to the translocation of NFκB dimers to 
the nucleus [15, 16]. Activation of cancer- and host-spe-
ciic NFκB signalling by these factors plays a key role in 
the initiation and progression of cancer related osteolytic 
and osteosclerotic bone metastases [17–21].
The skeleton is a common site of metastasis in advanced 
prostate cancer. The homing, colonization and growth of 
metastatic prostate cancer cells in the skeleton are major 
causes of pathological fractures and bone pain in advanced 
cancer patients [22–24]. The majority of prostatic bone 
metastases in patients are predominately osteosclerotic and 
are frequently accompanied by enhanced osteoblast difer-
entiation and ectopic bone formation [25, 26]. However, 
the ability of prostate cancer cells to enhance the forma-
tion, survival and activity of osteoclasts by both directly 
and indirectly acting on osteoblasts, also contributes to the 
development of osteolytic lesions [24, 26–31].
A number of studies have implicated NFκB in the initia-
tion, progression and bone metastasis of prostatic tumours 
[10, 29, 32–42]. NFκB plays a role in the growth and meta-
static spread of androgen-independent prostate cancer cells 
[35–37], and pharmacological inhibition and knockdown 
of key components of NFκB signalling such as IKK have 
been found to reduce prostate cancer cell growth and 
metastasis [10, 29, 32–38, 43]. We have recently reported 
that a veriied inhibitor of canonical NFκB signalling, Par-
thenolide (PTN) [44–46], reduced breast cancer associ-
ated bone disease in mouse models [47–49]. Inhibition of 
NFκB has been found to enhance osteoblast diferentiation 
and maturation in the presence [47, 49] or absence [19] 
of cancer cells, however the efects of NFκB inhibitors on 
the ability of prostate cancer cells to inluence osteoblast 
diferentiation, osteoclast formation and osteolysis has not 
been investigated. In the present study, we show that PTN 
inhibited prostate cancer cell-related NFκB activation in 
osteoclasts and osteoblasts, reduced osteoclast formation 
and enhanced osteoblast diferentiation in the presence 
of cancer cells in vitro and increased bone volume in an 
ex vivo model of prostate cancer cell—calvarial organ co-
culture system.
Materials and Methods
Reagents and Cells
The sesquiterpene lactone, parthenolide (PTN) was pur-
chased from Tocris Biosciences (Bristol, UK). The human 
androgen-sensitive prostatic cancer cell line, LNCaP and 
the human castration-resistant cell lines PC3 and DU145 
were purchased from the ATCC (Manassas, VA). The rat 
Mat-Ly-Lu cells were a gift from Professor Daniel Chap-
pard (INSERM, Angers, France). The LNCaP bone meta-
static derivative C4-2B4 was a kind gift from Dr. Ning 
Wang (University of Sheield). The murine RM1-BT pros-
tate cancer cells were a kind gift from the laboratory of 
Dr. Martina Rauner and Professor Lorenz Hofbauer (Dres-
den, Germany). All cancer cell lines were grown in Dul-
becco’s Modiied Eagle Medium (DMEM), obtained from 
Sigma–Aldrich (Dorset, UK) with 10% foetal calf serum. 
Primary bone marrow derived macrophages, mature oste-
oclasts and calvarial osteoblasts were cultured in alpha-
Modiied Eagle Medium (αMEM). Primers for quantita-
tive PCR were obtained from Invitrogen (Paisley, UK) 
and probes were purchased from Roche Diagnostics Ltd. 
(East Sussex, UK). Western blot antibodies were obtained 
from Cell Signalling Biotechnology (MA, USA) except 
rabbit anti-actin was purchased from Sigma–Aldrich (Dor-
set, UK). Mouse macrophage-colony stimulating factor 
(M-CSF) was obtained from R&D Systems (Abingdon, 
UK) and RANK ligand (RANKL) was a gift from Patrick 
Mollat (Galapagos SASU, France) [47].
Cell Viability
The efect of Parthenolide on cell viability was measured 
by Alamar Blue as described in [50]. Prostate cancer cells 
(1 × 103 cells/well) were cultured in serum free DMEM 
and M-CSF dependent osteoclast precursors or calvarial 
osteoblast (10 × 103 cells/well) were cultured in stand-
ard αMEM medium in the presence of vehicle (DMSO) 
or PTN at the desired concentration and for the period 
indicated.
Cell Adhesion and Spreading
The efects of Parthenolide on cell adhesion and spread-
ing were measured using the XCELLigence system [51]. 
Briely, standard DMEM medium containing vehicle or 
PTN was added to the E-plate (16-wells) and a base read-
ing for normalisations was calculated. Prostate cancer cells 
(9 × 103 cells/well) were then added in standard DMEM 
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supplemented with vehicle (0.1% bovine serum albumin 
in PBS) or RANKL (100 ng/ml) and cell adhesion and 
spreading were measured as previously described [51].
Cancer Cell: Mouse Calvaria Organ Co‑culture 
System
The efects of PTN on the development of prostate can-
cer related osteolysis were measured using an adaptation 
of the ex vivo mouse calvarial organ culture system [47]. 
Briely, murine calvaria were isolated from 7-day-old [C57/
Bl6] mice, divided in half equally along the medium sagit-
tal suture and each half was cultured on stainless steel rafts 
in 48-well plates. The standard alpha-MEM tissue culture 
medium containing test agents was changed every 48 h and 
the cultures were terminated on day 7. The experimental 
protocol was approved by the Ethics Committee at the Uni-
versity of Edinburgh and was conducted in accordance with 
the UK Home Oice regulations.
Micro‑computed Tomography
Bone volume was measured at the calvarial bone using 
microCT analysis [Skyscan 1172 instrument (Brucker, Bel-
gium)] at a resolution of 5 µm [52]. Images were recon-
structed by the Skyscan NRecon program and analysed using 
Skyscan CTAn software (Brucker, Belgium).
Osteoclast Cultures
Bone marrow (BM) cells were lushed from the long bones 
of 3–5 week old mice as previously described [53]. M-CSF 
dependent bone marrow macrophages (osteoclast precur-
sors) were plated into 96-well plates (15 × 103 cells/well) 
in standard alpha-MEM supplemented in the presence of 
M-CSF (100 ng/ml) for 48 h and then and in M-CSF (25 ng/
ml) and RANKL (100 ng/ml) for up to 5 days. For stud-
ies involving prostate cancer cells and their derived factors, 
M-CSF (25 ng/ml) and RANKL (100 ng/ml) were added 
6 h prior to the addition of prostate cancer cells (300 cells/
well) or their conditioned medium (20% v/v) prepared as 
previously described [53] Cultures were terminated by ixa-
tion in 4% paraformaldehyde, and mature osteoclasts were 
identiied by Tartrate-Resistant Acid Phosphatase (TRAcP) 
staining [53]. Osteoclast activity was assessed by measur-
ing resorbed area in mature osteoclasts cultured on Corn-
ing® Osteo Assay Surface multiple well plates (Corning, 
USA). Resorption pits were visualized on an Olympus 
ScanR microscope and resorbed area was quantiied by using 
ImageJ software.
Osteoblast Cultures
Primary osteoblasts were isolated from the calvarial bones of 
2-day-old mice as described previously [54]. Calvarial osteo-
blasts (1 × 105 cells/well) were cultured in standard alpha-
MEM for the desired period and osteoblast cell number and 
diferentiation were determined by AlamarBlue assay and 
alkaline phosphatase (Alk Phos) assays, respectively [54].
Assessment of DNA Fragmentation and Apoptosis
Adherent and non-adherent cells were collected, ixed with 
4% paraformaldehyde and cytospun into glass slides. Apop-
tosis was identiied using DAPI staining and TUNEL stain-
ing [55]. An average of 6 microscopic ields per group was 
analysed at ×200 magniication and the number of apoptotic 
cells were quantitated in relation to total cell number.
Western Blotting
Western blot analysis was used to detect the expression 
of total proteins and their phosphorylated forms in pros-
tate cancer and bone cells. Briely, cells were incubated in 
serum free medium with or without test agents for 60 min 
and then cells were treated with cytokines or conditioned 
medium from cancer cells and homogenized and collected 
in lysis bufer (0.1% (w/v) SDS, 0.5% (w/v) sodium deoxy-
cholate, 1% Triton X-100, 1 mMEDTA, 2% (v/v) protease 
inhibitor cocktail, 10 mM of sodium luoride and 2% (v/v) 
phosphatase inhibitor cocktail). Protein concentration was 
determined using BCA assay (Pierce, USA). Total protein 
(50–70 µg) was resolved by SDS–PAGE (BioRAD, UK) and 
immunoblotted and native and phosphorylated proteins were 
detected by using the indicated rabbit monoclonal antibod-
ies (all at 1:1000 dilution), and immuno-complexes were 
visualized using chemiluminescence (Amersham, UK) on a 
Syngene GeneGnome imaging system. Bands were quanti-
ied using GeneSnap software (Syngene, UK) and level of 
actin (Sigma–Aldrich, UK) was used for normalization.
Quantitative PCR
Quantitative PCR (qPCR) was used to detect RANKL 
and osteoprotegerin (OPG) gene expression in calvarial 
osteoblasts. Briely, RNA was quantiied using a nanodrop 
(Thermo Scientiic) and complementary DNA (cDNA) was 
generated using Invitrogen SuperScript III Reverse Tran-
scriptase kit according to manufacturer’s instructions. For 
ampliication of mouse OPG (forward primer: 5ƍ- ATG AAC 
AAG TGG CTG TGC TG-3ƍ, reverse primer 5ƍ-CAG TTT CTG 
GGT CAT AAT GCAA-3ƍ); mouse RANKL (forward primer: 
5ƍ-TGA AGA CAC ACT ACC TGA CTC CTG -3ƍ, reverse primer 
5ƍ-CCA CAA TGT GTT GCA GTT CC -3ƍ); mouse GAPDH 
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(forward primer: 5ƍ- CCT GAA TTT TAA GCT ACA CAC AGC 
-3ƍ, reverse primer 5ƍ- CTG GCA CTG CAC AAG AAG AT -3ƍ) 
were used. GAPDH was used for cDNA normalization.
Statistical Analysis
Comparison between groups was assessed by analysis of 
variance (ANOVA) followed by Dunnet’s post hoc test 
(SPSS for Windows, version 11). A p-value value of 0.05 or 
below was considered statistically signiicant. The half max-
imal inhibitory concentration (IC50) values were calculated 
using GraphPad Prism 7 software (V10, Microsoft, USA).
Results
Parthenolide Inhibits the Growth of Prostate Cancer 
Cells In Vitro
A body of work has implicated NFκB signalling in the pro-
gression of prostate cancer cells from androgen sensitive to 
androgen independence [29, 32, 35–39]. With this in mind, 
we irst assessed the cytotoxic efect of the veriied NFκB 
inhibitor PTN on the in vitro viability of a panel of prostate 
cancer with diferent abilities to metastasise to the skeleton. 
As shown in Fig. 1, PTN (0.001–100 µM) reduced the via-
bility of the human androgen-sensitive prostatic cancer cell 
line LNCaP and its metastatic sub-clone C42-B4, human 
castration-resistant cell lines PC3 and DU145, mouse RM1-
BT and rat Mat-Ly-Lu in a concentration-dependent manner. 
The concentration of this compound that half maximally 
inhibited cell viability (IC50) was signiicantly lower in the 
metastatic PC3, RM1-BT and DU145 cells when compared 
to other cell lines tested (Table 1).
Parthenolide Reduces Prostate Cancer Related 
Osteoclast Formation In Vitro
NFκB plays a key role in RANKL-induced osteoclas-
togenesis [11–13], and previous studies have shown that 
PTN reduces osteolysis in models of breast cancer bone 
metastasis [44–49]. Here, we tested the efects of PTN on 
the ability of prostate cancer cells to inluence RANKL-
induced osteoclastogenesis in vitro. To investigate this, we 
irst assessed the ability of a panel of human and murine 
prostate cancer cell lines to enhance osteoclast formation 
in cultures of mouse M-CSF generated bone marrow mac-
rophage (osteoclast precursors) at various concentrations of 
RANKL (5–100 ng/ml). These experiments revealed that 
pre-treatment of osteoclast precursors to the prostate cancer 
cells Mat-Ly-Lu—but not PC3 and RM1-BT (Fig. 2a and 
data not shown) or their derived factors (Fig. 2b and data 
not shown) enhanced RANKL-induced osteoclast formation 
(p < 0.001). Furthermore, exposure of osteoclast precursors 
to PTN (0.1–1 µM) for 1 h prior to the addition of Mat-Ly-
Lu, PC3, RM1-BT or their derived factors reduced osteo-
clast formation in these cultures (Fig. 2a, b). Representative 
photomicrographs of TRAcP positive multi-nucleated osteo-
clasts from the prostate Mat-Ly-Lu—osteoclast co-cultures 
described are shown in Fig. 2c.
Parthenolide Inhibits Prostate Cancer Related 
Osteoclast Motility In Vitro
RANKL is an essential regulator of motility of osteoclasts 
and their precursors [56, 57]. Here, we show that Mat-Ly-
Lu conditioned medium induced adhesion and spreading 
of RANKL and M-CSF generated osteoclast precursors 
(Fig. 3a) and this efect was completely abolished in cul-
tures treated with PTN (0.1 µM) treated cultures completely 
abolished by PTN (0.1 µM) after 6 h. In contrast, PTN 
(0.1–1.0 µM) had no efects on the proliferation of RANKL 
and M-CSF generated osteoclast precursors for up to 24 h at 
concentration tested (Fig. 3b), thus excluding the possibility 
that the inhibitory efect on osteoclast motility was mediated 
by a reduction in cell viability in the experiment described.
Parthenolide Inhibits Prostate Cancer Related 
Osteoclast Survival In Vitro
Next, we went on to carry out additional experiments on the 
efects of PTN on mature osteoclast activity and survival. 
Mature osteoclasts were generated in RANKL and M-CSF 
stimulated bone marrow macrophage cultures for 3 days, and 
then exposed to rat Mat-Ly-Lu conditioned medium (20% 
v/v) in the presence and absence of Parthenolide (PTN). The 
results of this experiment revealed that the ability of mature 
osteoclasts to form resorption pits in vitro was only reduced 
by PTN at 30 µM (Fig. 3c)—a concentration that signii-
cantly decreased the survival of mature osteoclasts in the 
model described (Fig. 3d). At 1 µM, PTN had no efects on 
bone resorption or survival of mature osteoclasts (Fig. 3c, d).
Parthenolide Reduces Osteoblast Support 
for Osteoclast Formation In Vitro
Osteoblasts are an essential source of RANKL [58]. In 
view of this, we next tested the efects of PTN on osteoblast 
Fig. 1  Parthenolide inhibits the viability of a panel of prostate cancer 
cells in vitro. a–f The efects of Parthenolide (PTN, 0.001–100 µM) 
on the viability of human androgen-sensitive prostatic cancer LNCaP 
(a) and its metastatic sub-clone  LNCaPC42-B4 (b) and castration-
resistant human PC3 (c) and DU145 (d), mouse RM1-BT (e) and rat 
Mat-Ly-Lu (f). Cell viability was assessed by AlamarBlue assay. G. 
Representative photomicrographs of Mat-Ly-Lu treated with PTN for 
72 h at the indicated concentrations. *p < 0.05 and **p < 0.01
◂
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support for osteoclastogenesis in the presence of derived 
factors from prostate cancer cell. Conditioned medium from 
the prostate Mat-Ly-Lu cells was used in these experiments 
on the basis that these cells enhanced osteoclast formation 
in RANKL stimulated bone macrophage cultures (Fig. 4). 
Pre-treatment of calvarial osteoblasts with PTN (1 µM) 
prior to the addition of condition medium from Mat-Ly-Lu 
cells and bone marrow macrophages reduced the increase 
of RANKL/OPG ratio after 24 h (Fig. 4a), and inhibited 
osteoclast formation after 48 h (Fig. 4b). At 5 µM, PTN 
completely abolished the increase in osteoclast number by 
condition medium from Mat-Ly-Lu cells in calvarial osteo-
blast cultures (Fig. 4b).
Table 1  Efects of Parthenolide 
on the viability of human, 
mouse and rat prostate cancer 
cells in vitro
Cell viability were measured 
after 72  h of continuous expo-
sure to PTN by AlamarBlue 
assay. Calculation of half maxi-
mal inhibitory concentrations 
(IC50) has been performed as 
described under “Materials and 
Methods”. Values are expressed 
as means ± SD and are obtained 
from 3 independent experiments
Cell viability 
 (IC50, µM)
LNCaP 8.9 ± 1.9
LNCaP—C42B4 43.8 ± 4.1
PC3 2.7 ± 1.1
DU145 4.7 ± 1.9
RM1-BT 3.9 ± 0.4
Mat-Ly-Lu 18.7 ± 2.8
Fig. 2  Parthenolide inhib-
its prostate cancer cell- and 
RANKL-related osteoclastogen-
esis in vitro. a, b. Osteoclast 
formation in murine M-CSF 
(25 ng/ml) and RANKL 
(100 ng/ml) stimulated bone 
marrow macrophage (pre-osteo-
clasts) cultures after exposure to 
rat Mat-Ly-Lu, human PC3 and 
mouse RM1-BT prostate cancer 
cells (a) or their conditioned 
medium (20% v/v) (b) in the 
presence and absence of Parthe-
nolide (PTN) at the indicated 
concentration for 48 h. C Rep-
resentative photomicrographs of 
TRAcP positive multi-nucleated 
osteoclasts from the experiment 
described in panel b. *p < 0.05 
from vehicle and +p < 0.05 from 
vehicle treated with conditioned 
medium
Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In…
1 3
Fig. 3  Parthenolide inhibits prostate cancer cell- and RANKL-related 
osteoclast motility and survival in vitro. a, b Pre-osteoclast adhesion 
and spreading (a) and number (b) in cultures of murine M-CSF-
dependent bone marrow macrophage after exposure to rat Mat-Ly-Lu 
conditioned medium (20% v/v) in the presence and absence of Par-
thenolide (PTN) at the indicated concentration for 6 h. Cell motility 
and viability were assessed by real-time cell analyzer xCELLigence 
and AlamarBlue assay, respectively. c In  vitro bone resorption in 
mature osteoclast cultures. Mature osteoclasts were generated in 
RANKL and M-CSF stimulated bone marrow macrophage cultures 
for 3 days, and then exposed to rat Mat-Ly-Lu conditioned medium 
(20% v/v) in the presence and absence of Parthenolide (PTN) at the 
indicated concentration for 72 h. d Total osteoclast number from the 
experiment described in panel c as assessed by TRAcP staining. Val-
ues are mean ± SD. *p < 0.05 from vehicle and +p < 0.05 from vehicle 
treated with conditioned medium. AU denotes arbitrary unit
Fig. 4  Parthenolide enhances osteoblast diferentiation and reduces 
their support for osteoclastogenesis in  vitro. a RANKL and OPG 
mRNA expression in mouse calvarial osteoblasts exposed to condi-
tioned medium (20% v/v) from Mat-Ly-Lu prostate cancer cells after 
24 h in the presence and absence of PTN (1 µM). b Osteoclast for-
mation in mouse calvarial osteoblast—bone marrow cell co-cultures 
pre-treated with Mat-Ly-Lu conditioned medium (CM, 20% v/v) 
in the presence and absence of Parthenolide (PTN, 0.1–5 µM). c, d 
In  vitro osteoblast diferentiation (c) and viability (d) after 48  h in 
mouse calvarial osteoblasts exposed to standard medium or condi-
tioned medium from Mat-Ly-Lu prostate cancer cells in the presence 
and absence of PTN at the indicated concentration. Osteoblast dif-
ferentiation and viability were assessed by alkaline phosphatase (Alk 
Phos) and AlamarBlue assays, respectively. Values are mean ± SD. 
*p < 0.05 from vehicle and +p < 0.05 from vehicle treated with con-
ditioned medium
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Parthenolide Enhances Osteoblast Number 
and Diferentiation In Vitro
Osteoblastic lesions are observed in prostate cancer patients 
[28, 59]. Thus, we examined the efects of PTN on osteoblast 
proliferation and diferentiation in the presence of derived 
factors from the prostate Mat-Ly-Lu cells. Exposure of 
mouse calvarial osteoblasts to conditioned medium from 
the prostate Mat-Ly-Lu cells increased alkaline phosphatase 
activity (Fig. 4c) and viability (Fig. 4d), and these efects 
were signiicantly enhanced by PTN at concentrations as 
low as 0.01 µM. Together, these results indicate that PTN 
enhances in vitro osteoblast number and maturation at con-
centrations that inhibited osteoclast formation under the 
conditions described.
Parthenolide Disrupts Prostate Cancer Cell‑Related 
NFκB Activation in Bone Cells
Western blot analysis of cultures of calvarial osteoblasts and 
M-CSF-generated osteoclast precursors showed that condi-
tioned medium from Mat-Ly-Lu cells (20% v/v) enhanced 
the phosphorylation of IκB (Fig.  5a, b) and ERK42/44 
MAPK (Fig. 5c, d) after 18 min (Fig. 5). Pre-treatment of 
osteoblasts and osteoclast precursors with PTN (20 µM) for 
1 h prior to addition of conditioned medium reduced the 
phosphorylation of IκB but not ERK1/2 (Fig. 5). These data 
indicate that Parthenolide disrupts the activation of the IκB/
NFκB signalling pathway by Mat-Ly-Lu derived factors.
Parthenolide Enhanced Bone Volume Without 
Tumour Cell Inhibition
We took advantage of the cancer cell—mouse calvarial organ 
co-culture system (Fig. 6a) to assess whether PTN preserve 
bone volume in the presence of the prostate Mat-Ly-Lu cells. 
Fig. 5  Parthenolide inhibits prostate cancer cell induced NFκB acti-
vation in osteoclasts and osteoblasts in  vitro. Western blot analysis 
of total and phosphorylated IκB and ERK42/44 MAPK in cultures 
of RANKL (100 ng/ml) and M-CSF (25 ng/ml) osteoclasts (left) and 
calvarial osteoblasts (right) pre-treated with PTN at the indicated 
concentration for 1 h and exposed to conditioned medium (CM, 20% 
v/v) from the rat prostate cancer cells Mat-Ly-Lu for 18 min. Values 
are mean ± SD. *p < 0.05 from vehicle and +p < 0.05 from vehicle 
treated with conditioned medium
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Fig. 6  Parthenolide preserves bone in an ex  vivo model of pros-
tate cancer osteolysis. a Graphic representation of mouse calvaria 
organ—prostate cancer cell co-culture system. b Bone volume (BV/
TV, %) in mouse calvaria bone from 7-day-old C57BL/6 mice co-
cultured with Mat-Ly-Lu cells in the presence and absence of vehicle 
or PTN (1 µM). c Representative photomicrographs of microCT scan 
of mouse calvaria bone from the experiment described in panels a, 
b. d The efects of PTN (1 µM) on the viability of Mat-Ly-Lu pros-
tate cancer cells from the experiment described in a–c as assessed 
by AlamarBlue assay. e, f In vitro caspase-3 activation (e) and DNA 
fragmentation and apoptosis (f) in Mat-Ly-Lu cells in the presence 
and absence of PTN at indicated concentration for 7 days as assessed 
by Western Blot analysis and TUNEL assay, respectively. Values are 
mean ± SD. *p < 0.05 from vehicle and $p < 0.05 from PTN (10 µM). 
cC3 denotes cleaved caspase-3
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MicroCT analysis of the calvarial bone in these experiments 
conirmed that PTN (1.0 µM) signiicantly enhanced bone 
volume after 7 days of continuous treatment. Representa-
tive microCT images of calvarial bone from the experiment 
described are shown in Fig. 6c. To exclude the possibility 
this efect was due to the anti-proliferative efects of PTN 
on cancer cells, we went on to show that PTN (1.0 µM) had 
no efects on the viability of Mat-Ly-Lu cells in the mouse 
calvarial organ co-culture system (Fig. 6d), and it failed to 
induce caspase-3/7 activation (Fig. 6e) or cause nuclear con-
densation and DNA fragmentation (Fig. 6f).
Discussion
Cancer associated bone disease is a serious complication of 
metastatic prostate cancer [22–24]. The growth and expan-
sion of prostatic tumour cells in the skeleton coupled with 
the development of osteosclerotic and osteolytic lesions are 
the causes of morbidity in patients with advanced disease 
[24, 26–31]. NFκB signalling pathway has been implicated 
in the initiation, progression and bone metastasis of prostate 
cancer [10, 29, 32–43]. In view of the fact that the canonical 
NFκB signalling pathway plays a major role in the regulation 
of bone growth, osteoclastic bone resorption and osteoblas-
tic bone formation [11–13], we employed a pharmacologi-
cal approach to test if the veriied inhibitor of the canonical 
NFκB signalling pathway PTN disrupts the ability of pros-
tate cancer cells to inluence osteoclast formation, osteoblast 
diferentiation and osteolysis.
Prostate cancer cells interact with osteoblasts and clinical 
evidence suggests that prostate cancer osteoblastic lesions 
give rise to increased osteoclastic activity and thus osteolytic 
lesions and bone loss [25, 26]. Here, we provide in vitro 
evidence to show that PTN, acting on osteoblasts and oste-
oclasts, reduces prostate cancer cells and RANKL-related 
osteoclastogenesis. The evidence for this comes from the 
experiments in which PTN inhibited the ability of Mat-Ly-
Lu prostate cancer cells to enhance the spread and adhesion 
of bone marrow derived pre-osteoclasts and the formation 
of multi-nucleated osteoclasts in the presence of RANKL or 
calvarial osteoblasts. Furthermore, PTN also inhibited the 
survival of mature osteoclast survival in the presence of con-
ditioned medium from Mat-Ly-Lu cells, but it had no direct 
efect on osteoclastic bone resorption at concentrations that 
do not inhibit osteoclast survival. An interesting observation 
of our present study is that human PC3 and mouse RM1-BT 
and their derived factors—but not Mat-Ly-Lu cells—failed 
to enhance RANKL-induced osteoclast formation in our 
models. We cannot readily explain this except to note that 
previous studies have shown that prostate cancer cells such 
as PC3 and DU145 produce the RANKL decoy receptor 
OPG [60].
Mechanistic data showed that PTN reduced RANKL/
OPG production by osteoblasts and inhibited both RANKL 
and Mat-Ly-Lu conditioned medium induced IκB phospho-
rylation in osteoblasts and osteoclasts. These indings are 
of interest in suggesting that NFκB inhibition suppresses 
osteoclast formation stimulated by RANKL as well as other 
NFκB stimulating prostate cancer-derived factors such as 
TNFα and ILβ that are known to be present in the bone 
metastatic microenvironment [24, 26–31]. Of note, PTN had 
no efects on the activation of ERK1/2 by prostate cancer-
derived factors, conirming the speciicity of this agent to 
the canonical NFκB signalling.
Prostate cancer cells in bone promote osteoblastic bone 
metastasis [25, 26]. In support of previous studies that have 
shown that inhibition of NFκB enhances osteoblast difer-
entiation and maturation in the presence [47, 49] or absence 
[19] of cancer cells, we have found that PTN increased the 
ability of Mat-Ly-Lu prostate cancer cells to enhance oste-
oblast diferentiation and cell number. The ability of this 
compound to enhance osteoblast diferentiation and reduce 
osteoclastogenesis is broadly consistent with its osteopro-
tective efects in the calvarial organ - of Mat-Ly-Lu cell 
co-culture system. It is important to note that the osteo-
protective efects of PTN in our model was achieved at a 
concentration of 1 µM that had no efects on the viability 
or apoptosis of the Mat-Ly-Lu prostate cancer cells tested, 
thereby excluding prostate cancer cell growth inhibition in 
this in vitro experiment. However, PTN (1 µM) signiicantly 
reduced the in vitro growth of Mat-Ly-Lu in the absence of 
the mouse calvarial. We cannot readily explain this except 
speculate that the presence of host-derived factors in the 
calvarial organ culture model may have contributed to the 
ex vivo growth inhibition by PTN. Notwithstanding this, 
our present data complement previous studies that reported 
that reduction of osteoclast bone resorption and stimula-
tion of osteoblast activity due to NFκB inhibition reduce 
bone loss induced by disorders that include bone metastasis, 
inlammation, oestrogen deiciency, rheumatoid arthritis and 
Paget’s disease of bone loss [2, 4, 6, 8–14]. One important 
caveat of our present study, however, is that the increase in 
osteoblast number and diferentiation by NFκB inhibition 
is likely to contribute to the development of prostate cancer 
related osteosclerosis—a common feature of prostate cancer 
bone metastasis in patients [25, 26].
In conclusion, our present indings conirm that inhibi-
tion of the canonical NFκB signalling pathway may have a 
potential role in protecting the skeleton from the osteoly-
sis associated with prostate cancer. When combined with 
previous studies [34–42], these indings suggest that NFκB 
inhibitors as both anti-metastatic and anti-osteoclastic agents 
may be of value in protecting against skeletal complications 
associated with prostate cancer bone metastasis. However, 
further studies are needed to explore the role of NFκB in 
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the initiation, development and progression of osteoblastic 
prostate cancer metastases, and ascertain whether, and to 
what extent, the promotion of osteoblast diferentiation by 
NFκB inhibitors may limit the usefulness of this class of 
agents for the treatment of osteoblast-driven cancer associ-
ated bone diseases such as prostate cancer and sarcomas. For 
that, further in vivo studies are needed and ongoing.
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